AU2002241611A1 - Orally-bioavailable formulations of fentanyl and congeners thereof - Google Patents
Orally-bioavailable formulations of fentanyl and congeners thereofInfo
- Publication number
- AU2002241611A1 AU2002241611A1 AU2002241611A AU4161102A AU2002241611A1 AU 2002241611 A1 AU2002241611 A1 AU 2002241611A1 AU 2002241611 A AU2002241611 A AU 2002241611A AU 4161102 A AU4161102 A AU 4161102A AU 2002241611 A1 AU2002241611 A1 AU 2002241611A1
- Authority
- AU
- Australia
- Prior art keywords
- congeners
- fentanyl
- orally
- bioavailable formulations
- bioavailable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25114400P | 2000-12-04 | 2000-12-04 | |
| US60/251,144 | 2000-12-04 | ||
| PCT/US2001/047651 WO2002045713A2 (fr) | 2000-12-04 | 2001-10-26 | Formulations a biodisponibilite orale de fentanyl et de congeneres |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002241611A1 true AU2002241611A1 (en) | 2002-06-18 |
Family
ID=22950663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002241611A Abandoned AU2002241611A1 (en) | 2000-12-04 | 2001-10-26 | Orally-bioavailable formulations of fentanyl and congeners thereof |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20020160991A1 (fr) |
| AU (1) | AU2002241611A1 (fr) |
| WO (1) | WO2002045713A2 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6974590B2 (en) | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US20030091629A1 (en) | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
| US6849263B2 (en) * | 1998-12-21 | 2005-02-01 | Generex Pharmaceutical Incorporated | Pharmaceutical compositions for buccal delivery of pain relief medications |
| US20040224010A1 (en) * | 2002-11-15 | 2004-11-11 | Optime Therapeutics, Inc. | Ophthalmic liposome compositions and uses thereof |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| WO2005065319A2 (fr) * | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Forme galenique de fentanyl generalement lineaire effervescente et orale et ses procedes d'administration |
| US7858121B2 (en) * | 2003-12-31 | 2010-12-28 | Cima Labs, Inc. | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
| CA2549642C (fr) * | 2003-12-31 | 2012-10-30 | Cima Labs Inc. | Formes galeniques d'opiates orales effervescentes et procedes d'administration d'opiates |
| US20070104763A1 (en) * | 2005-11-10 | 2007-05-10 | Navinta Llc | Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making |
| RU2432950C2 (ru) | 2006-01-25 | 2011-11-10 | Инсис Терапьютикс Инк. | Подъязычный спрей на основе фентанила |
| PT103884A (pt) * | 2006-11-17 | 2008-05-19 | Astrazeneca Ab | Composições de libertação prolongada e métodos para a sua preparação |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| NO2180844T3 (fr) * | 2007-08-02 | 2018-07-21 | ||
| EP2039360A1 (fr) * | 2007-09-19 | 2009-03-25 | Euro-Celtique S.A. | Administration directe non invasive d'opioïdes au système nerveux central |
| US20140179615A1 (en) * | 2012-07-12 | 2014-06-26 | Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd. | Glutathione and Acetaminophen Composition and Preparation Method Thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1196033B (it) * | 1984-02-22 | 1988-11-10 | Chiesi Farma Spa | Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche |
| US5180716A (en) * | 1990-08-01 | 1993-01-19 | The Regents Of The University Of California | Cyclodextrin complexes for neuraxial administration of drugs |
| US5231089A (en) * | 1991-12-02 | 1993-07-27 | University Of Florida | Method of improving oral bioavailability of carbamazepine |
| US5759573A (en) * | 1993-04-22 | 1998-06-02 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| US5451408A (en) * | 1994-03-23 | 1995-09-19 | Liposome Pain Management, Ltd. | Pain management with liposome-encapsulated analgesic drugs |
| US6635661B2 (en) * | 2000-05-25 | 2003-10-21 | Sepracor Inc. | Heterocyclic analgesic compounds and methods of use thereof |
| US6740639B1 (en) * | 2000-03-29 | 2004-05-25 | Council Of Scientific & Industrial Research | Inclusion complees of a high potent opioid peptide, pharmaceutical compositions and method of treatment |
-
2001
- 2001-10-26 WO PCT/US2001/047651 patent/WO2002045713A2/fr not_active Ceased
- 2001-10-26 AU AU2002241611A patent/AU2002241611A1/en not_active Abandoned
- 2001-10-26 US US10/014,321 patent/US20020160991A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20020160991A1 (en) | 2002-10-31 |
| WO2002045713A2 (fr) | 2002-06-13 |
| WO2002045713A3 (fr) | 2003-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2609901A (en) | Antimicrobial compositions and methods of use | |
| AU7362301A (en) | Bioadhesive compositions and methods of preparation and use | |
| AU2002241611A1 (en) | Orally-bioavailable formulations of fentanyl and congeners thereof | |
| EP1291377B8 (fr) | Compose de silicone et preparation cosmetique | |
| AU2001281140A1 (en) | Anti-plasmodium compositions and methods of use | |
| AU2001287023A1 (en) | Plasma-derived-fibrin-based matrices and tissue | |
| AU2001273074A1 (en) | Combinations of ssri and estrogenic agents | |
| AU2001295467A1 (en) | Skin cosmetic formulations | |
| AU2002225954A1 (en) | Dipeptidylpeptidases and methods of use | |
| AU2001269314A1 (en) | Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds | |
| AU2406299A (en) | Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect | |
| AU2002213422A1 (en) | Synthesis of 2-hydroxymethylglutamic acid and congeners thereof | |
| AU2001222986A1 (en) | Dehydroascorbic acid formulations and uses thereof | |
| AU4647200A (en) | Skin care compositions containing combination of skin care actives | |
| AU2001288682A1 (en) | Inhibition of cmv infection and dissemination | |
| IL156411A0 (en) | Hypoallergenic and non-irritant skin care formulations | |
| AU4361600A (en) | Skin care compositions containing combination of skin care actives | |
| AU2002221273A1 (en) | Delayed and sustained release formulations and method of use thereof | |
| AU4647300A (en) | Skin care compositions containing combination of skin care actives | |
| AU2002230781A1 (en) | Pharmaceutical uses and synthesis of benzobicyclooctanes | |
| AU2001265280A1 (en) | Preparation of 2-hydroxy-5-oxoproline and analogs thereof | |
| AU2001264863A1 (en) | Preparation of fagopyritols and uses therefor | |
| AU7522800A (en) | Synergistic insecticidal formulations of pyridaben and strobilurins | |
| AU2001249692A1 (en) | Phospholipid scramblases and methods of use thereof | |
| AU2001268236A1 (en) | Use of aicar and related compounds |